In a ratremnant kidney model of renal fibrosis, administration of the PPAR-γ agonisttroglitazone is associated with reduction of proteinuria, improved serumcreatinine, and glomerulosclerosis [8]. Here, PPARG is linked to glomerulosclerosis.